GBS CLINICAL TEAM MARKET UPDATE
GLP-1 Weight-Loss Drugs
Executive Summary
GLP-1 medications continue to dominate employer sponsored health plan discussions. Over the last 12-18 months the GLP‑1 market for obesity treatments has continued to evolve (at an increasing pace), leading many employers to revisit drug coverage decisions. In early 2025, the story was still defined by scarcity: patients bounced between pharmacies, prescribers chased backorders, and compounding / gray‑market supply filled the gaps while employers largely stayed on the sideline figuring out how or whether they can afford to offer weight loss drug coverage – as many found themselves reeling from the cost of GLP-1’s for type 2 diabetes. By early 2026, the center of gravity has shifted toward the following: (1) formal resolution of the highest‑profile shortages; (2) the first wave of oral obesity GLP‑1s (with oral semaglutide now on the market, and Lilly’s orforglipron lining up behind it for 2026); and (3) a scramble to make the economics work—via cash‑pay price moves, direct‑to‑consumer (DTC)/direct-to-employer (DTE) distribution.
Short Supply? No Longer
At the start of 2025, demand for Wegovy / Ozempic (semaglutide) and Zepbound / Mounjaro (tirzepatide) was still outpacing the industry’s ability to manufacture and distribute consistent supply across strengths. The practical impact for patients and clinicians was familiar: interrupted titration schedules, substitution across doses, and frequent “pharmacy shopping” behavior by patients.
The key turning points on the supply side challenges were the FDA lifting of the short supply designation in December 2024 for tirzepatide products and the February 2025 short supply cancellation on semaglutide. FDA shortage status is about national supply relative to demand, not whether a given dose is always sitting on the shelf at a pharmacy at any given time. Pharmacies continue to navigate GLP-1 sourcing operational challenges – balancing ordering (and cold storage requirements) against expected fills. It is best (i.e advisable, if not required) to give the pharmacy ample lead time on planned refills.
Short supply status controls the legal space in which compounding pharmacies can produce alternative versions of drugs that are essentially copies of commercially available products. Once FDA says a product is no longer in shortage, that “escape hatch” constricts. The safety and liability posture around compounding rises. With FDA approved GLP-1 weight loss products (made in FDA inspected sterile injectable manufacturing facilities) now widely available, the only remaining argument in favor of compounds becomes ‘cost’…and the market is rapidly evolving to address the affordability issue.
Oral (No Needle) GLP-1s Offer Greater Convenience at a Lower Price Point
After years of promise and patient waiting a safe and effective weight loss pill has finally come to market. Pharma has a somewhat checkered past as it relates to weight loss drug development – a history highlighted by drug clinical trial failures or market withdrawals due to dangerous cardiovascular side effects, addiction or psychiatric risks.
Novo Nordisk spent years building an oral semaglutide obesity program (the OASIS trials), largely because pills solve the hardest adoption problems at once: stigma, needle aversion, storage logistics, and (potentially) manufacturing scalability. In late 2025, FDA approved an oral version of Wegovy (“Wegovy pill”) as the first oral GLP‑1 for chronic weight management. The Wegovy pill launched in early 2026 and early prescription data shows it is off to a strong start – expanding the market and not adversely impacting Zepbound or Wegovy prescriptions (so far).
Eli Lilly’s orforglipron (note that this is NOT a “Zepbound pill”, but rather a new medication) is widely viewed as the most consequential “next” obesity pill because it is a small‑molecule GLP‑1 receptor agonist (not a peptide), designed for once‑daily oral dosing without the same absorption constraints that make peptide pills tricky. Orforglipron is expected to receive FDA approval in mid-2026.
The launch of the Wegovy pill, and anticipated near-term launch of orforglipron, has introduced a more affordable and more convenient alternative to the higher cost injectables. Two oral obesity GLP‑1s gives payers true therapeutic alternatives. Oral products are likely to intensify price pressure, because tablets are easier to distribute at scale and are more “retail pharmacy native” than cold‑chain injectable pens. It is likely that more patients will qualify (or seek prescriptions) earlier in disease progression with oral options compared to injectables.
Weight Loss Drugs – Transitioning to Consumer Market Products
The last 12 months saw a major strategic pivot: when insurance carriers/employer sponsored benefits plan balked at high prices for Wegovy and Zepbound (among other general affordability concerns around the large number of plan members that might qualify for treatment), and when manufacturers couldn’t (or wouldn’t) make broad list‑price cuts, they started building parallel cash‑pay channels with visibly lower “sticker” prices.
Enter Lilly Direct, NovoCare….and TrumpRx…DTC Platforms
Lilly used LillyDirect to sell authentic Zepbound in single‑dose vials at lower cash prices than the retail cash price of the prefilled pens. In 2025, Lilly cut self‑pay vial pricing for lower doses (e.g., reductions from the earlier $399/$549 price points down to roughly $349/$499 per month for 2.5 mg and 5 mg vials) and added additional dose options with “journey” / refill‑window pricing. The bigger message wasn’t the exact dollar figure, it was the architecture: a manufacturer‑controlled channel that can set a national cash price, reduce pharmacy variability, and (importantly) pull demand away from compounded products.
Novo launched NovoCare Pharmacy in 2025 with a widely cited $499/month cash‑pay offering for Wegovy injection across doses, explicitly positioning the program as a safety and authenticity alternative to compounded semaglutide. Since then, Novo has continued experimenting with lower price points and limited‑time offers, including lower introductory pricing for early doses and lower monthly pricing for ongoing self‑pay patients. That’s a sign the market is entering a new phase: price competition via programs, not just list price.
Novo further expanded its DTC distribution model through partnership with Hims & Hers (March 2026). In this deal, Novo will offer access to Ozempic and Wegovy tablets at its current self-pay pricing while Hims & Hers will shift its business model (and sizeable patient population) to focus on branded FDA-approved medicines.
TrumpRx: a Policy-Branded Coupon Layer
By early 2026, TrumpRx.gov entered the landscape as a federal platform that functions more like a navigator or coupon clearinghouse system than a traditional insurance benefit. The White House has promoted TrumpRx as part of a broader pricing and transparency push – individual shoppers are transitioned to Lilly Direct or NovoCare for fulfillment. For employers, the immediate question isn’t just “is it cheaper,” but “does it change utilization and employee expectations?” Even when TrumpRx is not a plan benefit, it can become a reference price that employees use to judge what their coverage should look like.
LillyDirect, NovoCare Pharmacy, and TrumpRx—are not just convenience features. They are strategic infrastructure in the new drug sourcing landscape.
Manufacturers like DTC for GLP‑1s as it provides them
›Control over price narrative (a clear cash price, rather than a chaotic pharmacy cash quote).
›Control over authenticity (a branded alternative to compounded or counterfeit supply).
›Control over data (adherence signals, refill cadence, patient support engagement).
›Reduced dependency on traditional retail pharmacy workflows.
With cash-pay seeming like a true win/win for drug manufacturers and patients, we anticipate the DTC drug sourcing model is here to stay.
“To Cover or Not to Cover?” That is the Question for Insurance Plans
While many very large employers have extended coverage for GLP-1s for weight loss to their plan members, most small to mid-size employers in our markets have not. For the vast majority, weight loss drugs remain a plan exclusion.
Employers ARE looking for solutions that can enable them to offer weight loss drug coverage, but with guardrails. They’re looking to dip a toe in but want to know the temperature of the pool before diving headfirst. Direct to employer (DTE) options are evolving to address this emerging demand.
DTE programs offer a mechanism for employers to cover some portion of the cost of weight loss drugs (say 50%) through a DTC direct purchase source like Lilly Direct or NovoCare – helping plan members with financial support while ensuring the lowest possible ‘cash’ pricing. With this model, plan financial exposure can be limited and coverage customized…avoiding the high-list pricing, PBM prior authorization and rebate requirements of traditional insurance coverage.
DTE took another step forward in early March 2026 when Eli Lilly announced the launch of Lilly Employer Connect, a new employer-focused platform designed to expand access to obesity management medications through a network of independent program administrators. Lilly Employer Connect is intended to give employers flexible, transparent benefit design options at a lower price point – effectively disintermediating the PBM high list price/rebate model that ties employers’ hands with broad and comprehensive coverage requirements in order to earn rebates to offset high list prices.
Holistic Support Remains an Important Consideration for Optimal Outcomes
GBS has long advocated for a best-practices model for the challenge of weight loss that includes lifestyle intervention with or without drug therapy. What has not changed over the past year is the fact that a large percentage of those starting GLP-1 drug therapy discontinue within the first 6-12 months, for a variety of reasons.
Surrounding plan members with an integrated wellness program can help better ensure plan member success on their weight loss journey.
Weight loss treatment should be considered “obesity care” – inclusive of nutrition coaching, behavioral support, outcomes monitoring and member specific strategies – and not simply drug coverage.
The Bottom Line
Obesity is a complex, chronic and progressive disease. Medications have a legitimate place in care – but the budget impact, long term use, and rising demand require a plan strategy that is intentional, consistent and defensible.
GBS can help you evaluate or formulate your plan strategy.
Please reach out to your GBS Team for more information.
